NCT00758160 - The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

296

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

OROS Methylphenidate

Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.